CART peptide and GPR160: how to test a disputed receptor assignment

1) Define the CART peptide reagent before testing biology

“CART peptide” is not a sufficient reagent description. ProCART processing yields multiple numbered fragments, and numbering can vary with the precursor convention and species. CART(55–102) and CART(62–102) are commonly studied long and short active forms. Record the full sequence, organism, residue numbering convention, terminal chemistry, counterion, net peptide content, and preparation method. If the experiment compares two fragments, verify each independently rather than assuming the shorter material is a simple concentration-adjusted version of the longer one.

The bioactive C-terminal region contains six cysteines arranged into three disulfide bonds. Intact mass alone confirms neither disulfide connectivity nor monomeric state: several incorrectly paired isomers can share the same mass. Combine reducing and nonreducing mass analysis with chromatographic purity, and use disulfide mapping when the mechanistic conclusion depends on native folding. Include aggregation and adsorption checks in the exact plasticware and matrix used for the assay. A low apparent potency can result from poor recovery, while a nonspecific response can come from aggregates or synthesis contaminants.

Prepare a small identity panel rather than relying on one reagent: correctly folded CART(55–102), CART(62–102), a sequence-matched reduced or deliberately misfolded control, and an unrelated disulfide-rich peptide of similar size. The controls should be exposed to the same handling history. When labeling CARTp for imaging or radioligand binding, qualify the conjugate as a new molecule by showing that unlabeled CARTp competes for its binding and that the label has not created cellular uptake or membrane affinity absent from the native peptide.

2) Treat GPR160 as a candidate, not settled nomenclature

A 2020 study proposed GPR160 as a CARTp receptor using cellular signaling, genetic or antibody perturbation, coimmunoprecipitation, fluorescent-peptide colocalization, and proximity measurements. CARTp increased cFOS or ERK-related readouts in selected cells, and perturbing GPR160 reduced responses; exogenous CARTp also appeared in close association with GPR160 in KATO III cells.^[1] These data support functional dependence and physical proximity in those experimental contexts, but they do not by themselves provide a saturable equilibrium affinity for purified CARTp at expression-matched GPR160 cells.

A direct-binding study published in 2023 reached the opposite conclusion. It reported no specific binding of radiolabeled CART(61–102) or CART(55–102) to GPR160-transfected U2OS or U-251 MG cells, and no specific binding in THP1 cells despite detectable endogenous GPR160. PC12 cells bound CARTp but did not show detectable GPR160 expression, and a GPR160 antibody did not compete for their CARTp sites.^[2] The authors therefore concluded that GPR160 did not account for the observed CARTp binding.

This disagreement should shape experimental language. Report “candidate GPR160-dependent CARTp signaling” when that is what the data show; reserve “CARTp–GPR160 binding” for a demonstrated molecular interaction. Cell background, receptor surface abundance, ligand form, label position, folding, and assay temperature could explain discordance, but these are hypotheses to test—not reasons to dismiss either result. A useful replication deliberately spans the conditions of both studies and changes one variable at a time.

3) Design binding assays that can establish—or falsify—direct recognition

Start with a receptor gain-of-function panel in at least two parental cell backgrounds. Generate GPR160-expressing and matched empty-vector cells, quantify cell-surface receptor with a validated extracellular tag or an orthogonal surface method, and avoid comparing total lysate expression alone. Add a positive control for membrane integrity and a separate assay showing that the GPR160 construct can reach the cell surface. If no independent reference agonist exists, surface delivery and construct integrity become especially important controls.

Measure total binding, nonspecific binding in a large excess of unlabeled peptide, and specific binding across a saturation series. Demonstrate time and temperature dependence, reversibility, and competition by unlabeled CART(55–102) and CART(62–102). A receptor claim should produce an expression-dependent binding component with finite capacity and reproducible affinity. Empty-vector cells, parental cells, and an unrelated GPCR expressed at comparable density reveal label-driven or host-cell binding. Repeating the experiment with label positions or with an orthogonal biophysical method helps rule out a tracer artifact.

Run the native-cell arm in parallel. PC12 cells are particularly informative because specific CARTp binding has been reported even where the 2023 study could not detect GPR160.^[2] Use competition and saturation analysis to establish a binding site, then compare its pharmacological profile with the recombinant system. Candidate-receptor knockout should remove the specific component; re-expression at near-endogenous abundance should restore it. If knockout changes signaling without changing binding, GPR160 may lie downstream of the binding protein rather than serving as the recognition site.

Coimmunoprecipitation, proximity ligation, and fluorescence colocalization are supportive but cannot replace equilibrium binding. A peptide may co-traffic with a receptor, associate through another membrane protein, or concentrate in the same endosomal compartment. Use crosslinking followed by proteomics as a discovery branch, with label-free competition and multiple negative-control peptides. Candidate hits should return to the gain/loss/rescue binding pipeline before being named receptors.

4) Connect binding to signaling without circular attribution

CARTp has been linked to ERK phosphorylation, CREB-related responses, and pertussis-toxin-sensitive signaling in cellular preparations, but such endpoints are shared by many receptors and stress pathways. The 2020 GPR160 study used ERK, cFOS, and CREB-associated responses as part of its functional case.^[1] These are useful phenotypic anchors, not receptor-specific fingerprints. Measure early kinetics, include vehicle and folding controls, and determine whether the response follows the concentration range that occupies the measured binding site.

Use a pathway panel with minimal amplification: direct or proximal G-protein activation where feasible, cAMP in both directions, calcium, β-arrestin recruitment, and short time-course ERK. Establish assay competence with controls that bypass CARTp. Compare GPR160 gain, knockout, and rescue across the same readouts while preserving raw baselines and maxima. A receptor-dependent signal that occurs only at concentrations far above binding saturation may reflect a second target, membrane disruption, or peptide impurity.

Antibodies require special caution. Antibody blockade can reflect receptor internalization, steric effects on a complex, Fc-dependent biology, or an unvalidated reagent. Verify specificity in knockout cells and reproduce the result genetically. Likewise, siRNA should be supported by multiple sequences, measured knockdown, and rescue with an RNA-resistant construct. If the receptor assignment depends on one antibody or one silencing reagent, it remains provisional.

5) Test receptor-independent and processing-dependent mechanisms

Not every CARTp effect needs to originate at a classical cell-surface receptor. A 2023 study of spinal inflammatory models reported a receptor-independent mechanism involving CART(55–102) processing, generation of an isoleucine–proline–isoleucine tripeptide, inhibition of dipeptidyl peptidase 4 (DPP4), and altered astrocyte inflammatory signaling.^[3] That work also distinguished actions of the intact globular peptide from its N-terminal region. The mechanistic lesson is broader than the model: peptide metabolism can create an active product whose target differs from the parent peptide’s binding site.

Measure parent peptide disappearance and product appearance in conditioned medium and cell extracts by targeted LC–MS. Include cell-free matrix controls, protease inhibitors chosen from a prespecified hypothesis, and authentic product standards. Test intact CARTp, identified fragments, and inactive sequence controls directly against the candidate enzyme. If a downstream phenotype persists after receptor knockout but follows fragment formation and enzyme inhibition, forcing it into a GPCR model will obscure the mechanism.

The same design protects against the reverse error. A stable CARTp response in a rapid signaling assay may be receptor-mediated even if a later endpoint is dominated by metabolism. Resolve seconds-to-minutes signaling from hours-long processing and phenotype measurements. Sampling only one late endpoint cannot distinguish receptor activation, enzymatic inhibition, cellular uptake, or degradation products.

6) A staged CARTp attribution workflow

1. Lock the reagent identity. State sequence, numbering, fold, purity, and recovered concentration.
2. Replicate both sides of the controversy. Include systems that previously supported GPR160 dependence and systems that separated CARTp binding from GPR160.
3. Require direct recognition. Demonstrate saturable, displaceable, expression-dependent binding before naming a receptor.
4. Use genetics causally. Pair loss with surface-expression-matched rescue and keep binding separate from downstream signaling.
5. Follow the peptide over time. Quantify intact CARTp and products so metabolism is not mistaken for receptor pharmacology.
6. Report uncertainty. Preserve negative results, assay windows, receptor abundance, tracer-specific activity, replicate definitions, and confidence intervals.

The strongest current conclusion is that CARTp is biologically active while its receptor identity remains unresolved. GPR160 dependence in some systems is a testable observation, not a substitute for direct binding, and the published negative binding data must be incorporated into any new deorphanization claim. A qualified ligand panel, matched recombinant cells, native-cell binding, knockout and rescue, orthogonal target discovery, and peptide-metabolism measurements can distinguish a direct receptor from a signaling partner or an entirely receptor-independent mechanism.